Rational Engineering of a Sub-Picomolar HIV-1 Blocker.
CCL5
CCR5
HIV-1
drug combination
entry inhibitor
protein engineering
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
31 10 2022
31 10 2022
Historique:
received:
09
09
2022
revised:
19
10
2022
accepted:
25
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
With the aim of rationally devising a refined and potent HIV-1 blocker, the cDNA of CCL5 5p12 5m, an extremely potent CCR5 antagonist, was fused to that of C37, a gp41-targeted fusion inhibitor. The resulting CCL5 5p12 5m-C37 fusion protein was expressed in
Identifiants
pubmed: 36366513
pii: v14112415
doi: 10.3390/v14112415
pmc: PMC9695723
pii:
doi:
Substances chimiques
Receptors, CCR5
0
Maraviroc
MD6P741W8A
CCR5 Receptor Antagonists
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Drug Des Devel Ther. 2015 Oct 01;9:5447-68
pubmed: 26491256
Science. 2001 Feb 2;291(5505):884-8
pubmed: 11229405
Trends Microbiol. 2019 Oct;27(10):878-891
pubmed: 31262533
Pharmacol Ther. 2022 Mar;231:107977
pubmed: 34480967
Annu Rev Immunol. 2020 Apr 26;38:673-703
pubmed: 32340576
J Virol. 2010 Jun;84(11):5842-5
pubmed: 20335248
J Biol Chem. 2011 Aug 12;286(32):28370-81
pubmed: 21659523
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Sci Rep. 2018 Jan 30;8(1):1890
pubmed: 29382912
Front Immunol. 2018 Jan 12;8:1981
pubmed: 29375583
Trends Pharmacol Sci. 2022 Jan;43(1):16-29
pubmed: 34742581
Immunity. 2017 Jun 20;46(6):1005-1017.e5
pubmed: 28636951
PLoS Pathog. 2022 Mar 31;18(3):e1010396
pubmed: 35358290
Elife. 2022 Jul 22;11:
pubmed: 35866628
Virol J. 2008 May 01;5:56
pubmed: 18452606
Front Immunol. 2022 Oct 20;13:956691
pubmed: 36341422
Protein Expr Purif. 2009 Nov;68(1):34-41
pubmed: 19573605
Int J Pharm. 2019 Jun 10;564:207-213
pubmed: 30999049
Nature. 2019 Dec;576(7787):397-405
pubmed: 31853080
Nat Med. 2021 Dec;27(12):2082-2084
pubmed: 34887576
AIDS Res Hum Retroviruses. 2021 Jun;37(6):453-460
pubmed: 33749321
J Virol. 1995 Jun;69(6):3712-20
pubmed: 7745720
Antimicrob Agents Chemother. 2010 Jul;54(7):2994-3001
pubmed: 20479208
Eur J Med Chem. 2018 Apr 25;150:206-227
pubmed: 29529501
Genes Dis. 2022 Jan;9(1):12-27
pubmed: 34514075
Front Immunol. 2022 Jan 20;12:816515
pubmed: 35126374
J Mol Biol. 2019 Aug 9;431(17):3091-3106
pubmed: 31255705
Nature. 2019 Jan;565(7739):318-323
pubmed: 30542158
J Biol Chem. 2005 Apr 1;280(13):12567-72
pubmed: 15657041
Nat Commun. 2021 Jul 6;12(1):4151
pubmed: 34230484
PLoS One. 2011;6(7):e22020
pubmed: 21760945
Expert Opin Drug Saf. 2021 Apr;20(4):397-409
pubmed: 33557651
Semin Immunol. 2021 Jan;51:101475
pubmed: 33858765
J Med Chem. 2018 Jun 14;61(11):5020-5033
pubmed: 29767965
Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):17706-11
pubmed: 19004761
Viruses. 2021 Jul 18;13(7):
pubmed: 34372601
J Med Chem. 2021 Aug 12;64(15):11460-11471
pubmed: 34261320
Antimicrob Agents Chemother. 2014 Oct;58(10):6215-23
pubmed: 25114130
Front Immunol. 2022 Jan 19;13:826418
pubmed: 35126399
Sci Adv. 2021 Jun 16;7(25):
pubmed: 34134983
J Leukoc Biol. 2018 Aug;104(2):323-331
pubmed: 29719064